Targeted radiation zaps recurrent kidney cancer in major new trial
NCT ID NCT07197580
Summary
This study is testing a new targeted radiation drug called 177Lu-TLX250 for people with advanced kidney cancer that has returned or spread after at least two prior treatments. The drug is designed to find and deliver radiation directly to cancer cells. The trial will first find the best dose, then compare the drug's effectiveness and safety against a standard single-drug therapy chosen by the doctor.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA (RCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Austin Health
Heidelberg, Victoria, 3084, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
GenesisCare, Fiona Stanley Hospital (Murdoch)
Murdoch, Washington, 6150, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Melbourne Theranostic Innovation Centre (MTIC)
Melbourne N., Victoria, 3051, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.